SAB-142 Phase 1 data shows C-peptide preservation in established T1D patients at Day 120

SAB Biotherapeutics, Inc.

T1D cohort (n=6): 4 treated with SAB-142 (2.5 mg/kg) showed no decline in C-peptide at Day 120; mean values increased above baseline.
Placebo participant (n=1) showed C-peptide decline consistent with predicted disease progression.
Biomarker evidence of T cell exhaustion supports mechanism of action, per KOL Michael Haller, MD.
SAFEGUARD Phase 2b trial enrolling new-onset Stage 3 T1D patients; topline data expected 2H 2027.
Phase 1 previously met safety/PD objectives, enabling advancement to registrational trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.